Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 2 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

Case Report: A potential cardiovascular safety signal during batroxobin therapy for sudden sensorineural hearing loss: a three-case series of acute myocardial infarction

  • Xin Zhuang1
  • Tianen Pan2
  • Kaiyu Hu3
  • Qianli Zhu3
  • Shengban You3
  1. 1Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University
  2. 2Department of Infectious Diseases, Pingyang Hospital of Traditional Chinese Medicine Zhejiang Chinese Medical University
  3. 3Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University
Open at sourceDOICite

Abstract

Background: Batroxobin, a defibrinogenating agent used as an adjunctive therapy for sudden sensorineural hearing loss (SSNHL), has an incompletely characterized cardiovascular safety profile.

Cases: We report three male patients with SSNHL who developed acute myocardial infarction (AMI) after batroxobin therapy. All three showed a precipitous fibrinogen decline (nadir: 0.48–0.75 g/L). AMI was diagnosed approximately 24–48 h after the final batroxobin dose. In Case 3, transient chest symptoms began on the day of the final dose and preceded the diagnosis of AMI the following day. Coronary angiography revealed varying degrees of underlying coronary abnormalities in all cases. One patient died of cardiogenic shock; the other two recovered after percutaneous coronary intervention.

Conclusion: In this case series, AMI occurred within 24–48 h after the final batroxobin administration in the context of marked fibrinogen reduction and underlying coronary abnormalities. These observations suggest a temporal association and raise a potential cardiovascular safety signal. Careful fibrinogen monitoring and individualized cardiovascular assessment may be considered in clinically appropriate patients.

Related

  1. Predictive value of combined estimated plasma volume status and neutrophil-to-lymphocyte ratio for cardiovascular mortality in patients with acute myocardial infarction with heart failure
    Caizhi Dai, Xiaomin Chen, Xiuting Chen +1
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  2. Community-Level Wastewater Surveillance of Nicotine Biomarkers Tracks Cardiovascular Disease Burden and Myocardial Infarction
    K. M. Joseph, X. Qin, K. M. Clark +10
    medRxivPreprintAll rights reservedFull textEpidemiology & public healthmedRxiv
  3. Mental Stress-Induced Myocardial Ischemia and Cardiovascular Events in Women after a Premature Myocardial Infarction: A Prospective Cohort Study
    V. Vaccarino, A. J. Shah, H. She +18
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  4. Real-life Psychological Experiences and Subsequent Cardiovascular Events among Survivors of a Myocardial Infarction in Midlife: Prospective Cohort Study
    V. Vaccarino, H. She, L. Elon +14
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  5. The relationship between endothelial activation and stress index (EASIX) and the incidence of major adverse cardiovascular events in acute myocardial infarction patients admitted in emergency department.
    Yan Cao, Bowen Xiong, Tangyi Zeng +3
    BMC emergency medicinePeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{zhuang2026case,
  title = {{Case Report: A potential cardiovascular safety signal during batroxobin therapy for sudden sensorineural hearing loss: a three-case series of acute myocardial infarction}},
  author = {Xin Zhuang and Tianen Pan and Kaiyu Hu and Qianli Zhu and Shengban You},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = nov,
  doi = {10.3389/fcvm.2026.1853445},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1853445/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Case Report: A potential cardiovascular safety signal during batroxobin therapy for sudden sensorineural hearing loss: a three-case series of acute myocardial infarction
AU  - Xin Zhuang
AU  - Tianen Pan
AU  - Kaiyu Hu
AU  - Qianli Zhu
AU  - Shengban You
PY  - 2026
DA  - 2026/11/09
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1853445
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1853445/full
AB  - Background: Batroxobin, a defibrinogenating agent used as an adjunctive therapy for sudden sensorineural hearing loss (SSNHL), has an incompletely characterized cardiovascular safety profile.  Cases: We report three male patients with SSNHL who developed acute myocardial infarction (AMI) after batroxobin therapy. All three showed a precipitous fibrinogen decline (nadir: 0.48–0.75 g/L). AMI was diagnosed approximately 24–48 h after the final batroxobin dose. In Case 3, transient chest symptoms began on the day of the final dose and preceded the diagnosis of AMI the following day. Coronary angiography revealed varying degrees of underlying coronary abnormalities in all cases. One patient died of cardiogenic shock; the other two recovered after percutaneous coronary intervention.  Conclusion: In this case series, AMI occurred within 24–48 h after the final batroxobin administration in the context of marked fibrinogen reduction and underlying coronary abnormalities. These observations suggest a temporal association and raise a potential cardiovascular safety signal. Careful fibrinogen monitoring and individualized cardiovascular assessment may be considered in clinically appropriate patients.
SN  - 2297-055X
ER  -